CombiGene announces a public offer to the holders of shares and warrants of series TO1 in Panion Animal Health

Apr 18, 2019

CombiGene discloses the information provided herein pursuant to the Takeover Rules and the EU:s Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 18 April 2019 at 08.30 a.m. CET.

Jan Nilsson (CEO)
+46704663163
jan.nilsson@combigene.com
Arne Ferstad (Chairman of the board)
+447496526142
arne.ferstad@ankor-consultants.com

Read more >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook